Infosys Secures Major NHS Contract Amidst Global Health Changes
Infosys has secured a $1.6 billion contract with UK's National Health Service. The contract aims to overhaul NHS's existing payroll platform amidst a challenging economic backdrop for the IT sector. New US COVID-19 guidelines have led to confusion, and BioCryst is acquiring Astria for $700 million, enhancing its rare diseases portfolio.
Infosys has announced a significant $1.6 billion contract win with the UK's National Health Services Business Services Authority. The deal, which spans 15 years, will see Infosys replace the existing payroll platform, marking a notable achievement for India's second-largest IT firm amid a challenging global economic climate.
Confusion has spread across the U.S. as new COVID-19 vaccination guidelines have resulted in roadblocks for Americans seeking shots. Vaccination rates have seen a significant drop, as recent data shows a 25% decrease, contributing to the lowest figures since vaccines were first introduced.
In other headlines, BioCryst Pharmaceuticals has announced a $700 million cash-and-stock acquisition of Astria Therapeutics, bolstering its focus on rare diseases. This transaction promises to enhance BioCryst's portfolio, despite fluctuations in both companies' stock values following the announcement.
Google News